Residual CV risk in patients on statin therapy
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CV risk reduction beyond statin therapy: Exploring the role of icosapent ethylPotential mechanisms of benefit of icosapent ethyl
Prof. Chris Packard, PhD
- CV risk reduction beyond statin therapy: Exploring the role of icosapent ethylExploring the role of icosapent ethyl based on current clinical evidence
Prof. Wouter Jukema, MD, PhD
- CV risk reduction beyond statin therapy: Exploring the role of icosapent ethylDiscussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl
Prof. Ulrich Laufs, MD, PhD
prof. Chris Packard, PhD prof. Wouter Jukema, MD, PhD
